Transcriptomic Analysis Reveals the Protective Effects of Empagliflozin on Lipid Metabolism in Nonalcoholic Fatty Liver Disease

Empagliflozin is a novel type of sodium-glucose cotransporter two inhibitor with diverse beneficial effects in the treatment of nonalcoholic fatty liver disease (NAFLD). Although empagliflozin impacts NAFLD by regulating lipid metabolism, the underlying mechanism has not been fully elucidated. In th...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Yuting Ma, Chengxia Kan, Hongyan Qiu, Yongping Liu, Ningning Hou, Fang Han, Junfeng Shi, Xiaodong Sun
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	Frontiers Media S.A. 2021-12-01
Σειρά:	Frontiers in Pharmacology
Θέματα:	empaglifiozin NAFLD obesity lipid transcriptome
Διαθέσιμο Online:	https://www.frontiersin.org/articles/10.3389/fphar.2021.793586/full
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!